Equities

Champions Oncology Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Champions Oncology Inc

Actions
Health CareHealth Care Providers
  • Price (USD)5.98
  • Today's Change-0.09 / -1.48%
  • Shares traded1.41k
  • 1 Year change-42.44%
  • Beta0.3985
Data delayed at least 15 minutes, as of Mar 03 2026 16:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.

  • Revenue in USD (TTM)58.42m
  • Net income in USD2.49m
  • Incorporated1985
  • Employees213.00
  • Location
    Champions Oncology IncOne University Plaza,, Suite 307HACKENSACK 07601United StatesUSA
  • Phone+1 (201) 808-8400
  • Fax+1 (302) 636-5454
  • Websitehttps://championsoncology.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tenax Therapeutics Inc0.00-43.33m72.55m4.00--0.7135-----1.13-1.130.0016.290.00----0.00-42.77-99.65-44.80-118.65------------0.00-------128.28------
Maia Biotechnology Inc0.00-22.34m76.66m13.00--1,711.40-----0.7504-0.75040.000.00120.00----0.00-212.50-208.29-602.02-373.18------------0.00-------17.61------
Fractyl Health Inc3.00k-122.20m76.98m107.00------25,659.14-2.27-2.270.00006-0.0240.00002----28.04-101.33-78.52-118.18-97.44100.00---4,073,233.00-122,747.90---31.401.12---22.50--25.29--78.65--
Protext Mobility Inc750.00-2.21m78.24m4.00------104,322.50-0.4692-0.46920.00001-0.01020.0405-------9,400.97-1,587.94----86.67-530.19-232,392.00-17,498.830.0002-1.36-----93.98-63.0927.35------
Seres Therapeutics Inc351.00k5.39m81.06m103.0015.211.808.39230.930.58920.58920.04044.990.0022----3,407.773.35-42.444.59-55.22----1,536.75-367.23----0.00------33.85---17.63--
Champions Oncology Inc58.42m2.49m84.29m213.0036.4220.2121.191.440.16670.16674.140.30032.11--5.31274,291.108.78-4.6733.91-11.6650.1147.284.16-2.79----0.0327--13.5412.13164.61---29.41--
Actuate Therapeutics Inc0.00-24.12m87.16m10.00--7.97-----1.19-1.190.000.47050.00----0.00-150.86---282.00--------------0.0357-------10.27------
Pyxis Oncology Inc2.82m-97.09m91.53m44.00--1.33--32.46-1.58-1.580.04571.110.0187----64,090.91-64.53-47.22-74.33-53.450.00---3,442.77-2,233.63----0.0006-------4.80------
Codexis Inc52.93m-63.95m92.13m188.00--2.39--1.74-0.7514-0.75140.62380.42690.3895.424.03281,553.20-47.00-21.95-58.53-26.2079.3176.67-120.82-49.884.02--0.5076---15.39-2.8214.38--2.91--
TuHURA Biosciences Inc0.00-43.77m92.30m19.00--4.72-----1.60-1.600.000.32730.00----0.00-286.97---456.76-------------9.010.0286--------------
Ibio Inc300.00k-24.74m92.92m20.00--1.43--309.74-1.26-1.260.01121.880.007----15,000.00-57.47-30.90-65.55-37.76-----8,245.67-2,374.12----0.00--77.78-24.57-19.00---57.50--
Cognition Therapeutics Inc0.00-27.99m93.57m25.00--2.56-----0.4816-0.48160.000.41380.00----0.00-78.86-59.00-108.44-75.05-----------3,450.080.00-------31.73---51.16--
Dogwood Therapeutics Inc0.00-39.98m93.89m12.00---------24.92-24.920.0033.750.00----0.00-81.05-52.48-84.58-55.93-----------178.510.00-------142.90------
Kazia Therapeutics Ltd (ADR)80.84k-14.68m94.47m12.00------1,168.68-12.31-12.310.0563-3.640.0083--0.0571---149.76-64.49---99.77-----18,159.65-573.31---------95.0911.5822.69------
Citius Oncology Inc3.94m-23.64m95.34m----1.57--24.17-0.3102-0.31020.05110.68890.03940.0426-----23.58---42.08--79.99---599.28--0.3245-112.340.0611-------17.08------
PMV Pharmaceuticals Inc0.00-82.71m95.78m63.00--0.7883-----1.58-1.580.002.280.00----0.00-46.29-21.46-49.90-22.32------------0.00------14.87--43.14--
Data as of Mar 03 2026. Currency figures normalised to Champions Oncology Inc's reporting currency: US Dollar USD

Institutional shareholders

16.06%Per cent of shares held by top holders
HolderShares% Held
West Elk Capital LLCas of 30 Sep 2024882.58k6.36%
Tocqueville Asset Management LPas of 31 Dec 2025319.67k2.30%
The Vanguard Group, Inc.as of 31 Dec 2025299.52k2.16%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025229.30k1.65%
Renaissance Technologies LLCas of 31 Dec 2025154.84k1.12%
BlackRock Fund Advisorsas of 31 Dec 2025119.62k0.86%
Mink Brook Asset Management LLCas of 31 Dec 202580.31k0.58%
Geode Capital Management LLCas of 31 Dec 202575.82k0.55%
Hightower Advisors LLCas of 31 Dec 202535.16k0.25%
Vanguard Fiduciary Trust Co.as of 31 Dec 202532.99k0.24%
More ▼
Data from 19 Feb 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.